REPORT ID 2929

Global Autoimmune Drugs Market Size, Status and Forecast 2022

Publish Date
12-Dec-17
Pages
115
Format
Electronic (PDF)

This report studies the global Autoimmune Drugs market, analyzes and researches the Autoimmune Drugs development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
    AbbVie
    Johnson & Johnson
    Biogen
    Amgen
    Pfizer
    F. Hoffmann-La Roche
    AstraZeneca
    GSK
    Merck
    Boehringer Ingelheim
    Novartis
    Sanofi
    Takeda Pharmaceuticals
    Eli Lilly
    Vertex Pharmaceuticals
    Eisai
    Antares Pharma
    UCB (Belgium)
    Acorda Therapeutics
    Lexicon Pharmaceuticals
    KaloBios Pharmaceuticals
    Can-Fite BioPharma
    Baxter
    Daiichi Sankyo
    Sandoz

Market segment by Regions/Countries, this report covers
    United States
    EU
    Japan
    China
    India
    Southeast Asia

Market segment by Type, the product can be split into
    TNF Inhibitors
    IL Blockers
    COX Inhibitors
    Phosphodiesterase Type 4 Inhibitors

Market segment by Application, Autoimmune Drugs can be split into
    Hospitals
    Clinics
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.


 
			   
Table of Contents

Global Autoimmune Drugs Market Size, Status and Forecast 2022
1 Industry Overview of Autoimmune Drugs
    1.1  Autoimmune Drugs Market Overview
        1.1.1 Autoimmune Drugs Product Scope
        1.1.2 Market Status and Outlook
    1.2 Global Autoimmune Drugs Market Size and Analysis by Regions
        1.2.1 United States
        1.2.2 EU
        1.2.3 Japan
        1.2.4 China
        1.2.5 India
        1.2.6 Southeast Asia
    1.3 Autoimmune Drugs Market by Type
        1.3.1 TNF Inhibitors
        1.3.2 IL Blockers
        1.3.3 COX Inhibitors
        1.3.4 Phosphodiesterase Type 4 Inhibitors
    1.4 Autoimmune Drugs Market by End Users/Application
        1.4.1 Hospitals
        1.4.2 Clinics
        1.4.3 Other

2 Global Autoimmune Drugs Competition Analysis by Players
    2.1 Autoimmune Drugs Market Size (Value) by Players (2016 and 2017)
    2.2 Competitive Status and Trend
        2.2.1 Market Concentration Rate
        2.2.2 Product/Service Differences
        2.2.3 New Entrants
        2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles
    3.1 AbbVie
        3.1.1 Company Profile
        3.1.2 Main Business/Business Overview
        3.1.3 Products, Services and Solutions
        3.1.4 Autoimmune Drugs Revenue (Value) (2012-2017)
        3.1.5 Recent Developments
    3.2 Johnson & Johnson
        3.2.1 Company Profile
        3.2.2 Main Business/Business Overview
        3.2.3 Products, Services and Solutions
        3.2.4 Autoimmune Drugs Revenue (Value) (2012-2017)
        3.2.5 Recent Developments
    3.3 Biogen
        3.3.1 Company Profile
        3.3.2 Main Business/Business Overview
        3.3.3 Products, Services and Solutions
        3.3.4 Autoimmune Drugs Revenue (Value) (2012-2017)
        3.3.5 Recent Developments
    3.4 Amgen
        3.4.1 Company Profile
        3.4.2 Main Business/Business Overview
        3.4.3 Products, Services and Solutions
        3.4.4 Autoimmune Drugs Revenue (Value) (2012-2017)
        3.4.5 Recent Developments
    3.5 Pfizer
        3.5.1 Company Profile
        3.5.2 Main Business/Business Overview
        3.5.3 Products, Services and Solutions
        3.5.4 Autoimmune Drugs Revenue (Value) (2012-2017)
        3.5.5 Recent Developments
    3.6 F. Hoffmann-La Roche
        3.6.1 Company Profile
        3.6.2 Main Business/Business Overview
        3.6.3 Products, Services and Solutions
        3.6.4 Autoimmune Drugs Revenue (Value) (2012-2017)
        3.6.5 Recent Developments
    3.7 AstraZeneca
        3.7.1 Company Profile
        3.7.2 Main Business/Business Overview
        3.7.3 Products, Services and Solutions
        3.7.4 Autoimmune Drugs Revenue (Value) (2012-2017)
        3.7.5 Recent Developments
    3.8 GSK
        3.8.1 Company Profile
        3.8.2 Main Business/Business Overview
        3.8.3 Products, Services and Solutions
        3.8.4 Autoimmune Drugs Revenue (Value) (2012-2017)
        3.8.5 Recent Developments
    3.9 Merck
        3.9.1 Company Profile
        3.9.2 Main Business/Business Overview
        3.9.3 Products, Services and Solutions
        3.9.4 Autoimmune Drugs Revenue (Value) (2012-2017)
        3.9.5 Recent Developments
    3.10 Boehringer Ingelheim
        3.10.1 Company Profile
        3.10.2 Main Business/Business Overview
        3.10.3 Products, Services and Solutions
        3.10.4 Autoimmune Drugs Revenue (Value) (2012-2017)
        3.10.5 Recent Developments
    3.11 Novartis
    3.12 Sanofi
    3.13 Takeda Pharmaceuticals
    3.14 Eli Lilly
    3.15 Vertex Pharmaceuticals
    3.16 Eisai
    3.17 Antares Pharma
    3.18 UCB (Belgium)
    3.19 Acorda Therapeutics
    3.20 Lexicon Pharmaceuticals
    3.21 KaloBios Pharmaceuticals
    3.22 Can-Fite BioPharma
    3.23 Baxter
    3.24 Daiichi Sankyo
    3.25 Sandoz

4 Global Autoimmune Drugs Market Size by Type and Application (2012-2017)
    4.1 Global Autoimmune Drugs Market Size by Type (2012-2017)
    4.2 Global Autoimmune Drugs Market Size by Application (2012-2017)
    4.3 Potential Application of Autoimmune Drugs in Future
    4.4 Top Consumer/End Users of Autoimmune Drugs

5 United States Autoimmune Drugs Development Status and Outlook
    5.1 United States Autoimmune Drugs Market Size (2012-2017)
    5.2 United States Autoimmune Drugs Market Size and Market Share by Players (2016 and 2017)

6 EU Autoimmune Drugs Development Status and Outlook
    6.1 EU Autoimmune Drugs Market Size (2012-2017)
    6.2 EU Autoimmune Drugs Market Size and Market Share by Players (2016 and 2017)

7 Japan Autoimmune Drugs Development Status and Outlook
    7.1 Japan Autoimmune Drugs Market Size (2012-2017)
    7.2 Japan Autoimmune Drugs Market Size and Market Share by Players (2016 and 2017)

8 China Autoimmune Drugs Development Status and Outlook
    8.1 China Autoimmune Drugs Market Size (2012-2017)
    8.2 China Autoimmune Drugs Market Size and Market Share by Players (2016 and 2017)

9 India Autoimmune Drugs Development Status and Outlook
    9.1 India Autoimmune Drugs Market Size (2012-2017)
    9.2 India Autoimmune Drugs Market Size and Market Share by Players (2016 and 2017)

10 Southeast Asia Autoimmune Drugs Development Status and Outlook
    10.1 Southeast Asia Autoimmune Drugs Market Size (2012-2017)
    10.2 Southeast Asia Autoimmune Drugs Market Size and Market Share by Players (2016 and 2017)

11 Market Forecast by Regions, Type and Application (2017-2022)
    11.1 Global Autoimmune Drugs Market Size (Value) by Regions (2017-2022)
        11.1.1 United States Autoimmune Drugs Revenue and Growth Rate (2017-2022)
        11.1.2 EU Autoimmune Drugs Revenue and Growth Rate (2017-2022)
        11.1.3 Japan Autoimmune Drugs Revenue and Growth Rate (2017-2022)
        11.1.4 China Autoimmune Drugs Revenue and Growth Rate (2017-2022)
        11.1.5 India Autoimmune Drugs Revenue and Growth Rate (2017-2022)
        11.1.6 Southeast Asia Autoimmune Drugs Revenue and Growth Rate (2017-2022)
    11.2 Global Autoimmune Drugs Market Size (Value) by Type (2017-2022)
    11.3 Global Autoimmune Drugs Market Size by Application (2017-2022)

12 Autoimmune Drugs Market Dynamics
    12.1 Autoimmune Drugs Market Opportunities
    12.2 Autoimmune Drugs Challenge and Risk
        12.2.1 Competition from Opponents
        12.2.2 Downside Risks of Economy
    12.3 Autoimmune Drugs Market Constraints and Threat
        12.3.1 Threat from Substitute
        12.3.2 Government Policy
        12.3.3 Technology Risks
    12.4 Autoimmune Drugs Market Driving Force
        12.4.1 Growing Demand from Emerging Markets
        12.4.2 Potential Application

13 Market Effect Factors Analysis
    13.1 Technology Progress/Risk
        13.1.1 Substitutes
        13.1.2 Technology Progress in Related Industry
    13.2 Consumer Needs Trend/Customer Preference
    13.3 External Environmental Change
        13.3.1 Economic Fluctuations
        13.3.2 Other Risk Factors

14 Research Finding/Conclusion

15 Appendix
    Methodology
    Analyst Introduction
    Data Source